# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $63 to ...
Wedbush analyst Robert Driscoll reiterates Arvinas (NASDAQ:ARVN) with a Outperform and maintains $57 price target.
Stifel analyst Bradley Canino maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $72 to $68.
HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $87 price target.
HC Wainwright & Co. analyst Andrew Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $90 ...
HC Wainwright & Co. analyst Andrew Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $90 ...
The deal is for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC androgen rece...